Werewolf Therapeutics (HOWL) announced the addition of WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease, IBD, and potentially other inflammatory diseases, to the Company’s pipeline. This pipeline expansion underscores the transformative promise of the Werewolf’s PREDATOR platform to apply the INDUKINE approach to therapeutic areas outside of oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL: